Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to define the course of the retinal degeneration in a ZSD patient cohort.
The objective of this study is to gather information so the investigators can:
At each yearly visit, the participants will answer a functional vision questionnaire, have a physical evaluation, blood test, and participate in a variety of vision tests. The investigators will also collect pertinent medical history.
Participants will travel to study site. The study will provide financial support for board and travel.
Participants/guardians will have a 1-hour virtual interview before the first visit to review the tests and determine which tests the participant is able to perform.
Below is a list of the vision tests used for this study:
Prior to each visit, the participant will complete the PedEyeQ or VFQ-25 questionnaire about functional vision.
At each clinic visit :
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with disease progression | Using various tests of vision measured annually, a description of disease progression will be defined in each participant. | 5 years |
| Number of participants with common patterns of retinal degeneration observed | Vision test results from participants will be reviewed together to describe common patterns of retinal degeneration observed. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of progression of retinal degeneration | Statistical analysis using the data from Outcome 1, will be used to generate rate of progression per year over 5 years in each individual. | 5 years |
| Correlation of rate retinal degeneration to age and overall ZSD disease severity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
any age, with appropriate diagnosis
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nancy E Braverman, MD, MS | Contact | 514-934-1934 | 23404 | nancy.braverman@mcgill.ca |
| Frederique Arnaud, BScN | Contact | 514-934-1934 | 23404 | frederique.arnaud@muhc.mcgill.ca |
| Name | Affiliation | Role |
|---|---|---|
| Nancy E Braverman, MD, MS | McGill University Health Centre/Research Institute of the McGill University Health Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Rochester Medical Center/Flaum Eye Institute | Recruiting | Rochester | New York | 14642 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26750748 | Background | Braverman NE, Raymond GV, Rizzo WB, Moser AB, Wilkinson ME, Stone EM, Steinberg SJ, Wangler MF, Rush ET, Hacia JG, Bose M. Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol Genet Metab. 2016 Mar;117(3):313-21. doi: 10.1016/j.ymgme.2015.12.009. Epub 2015 Dec 23. | |
| 37541626 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015211 | Zellweger Syndrome |
| D012164 | Retinal Diseases |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
Not provided
Not provided
Not provided
Not provided
Not provided
blood samples
Statistical analysis using the data from Outcome 1, will be used to correlate rate of progression per year over 5 years to age and overall ZSD disease severity in each individual. |
| 5 years |
| rate of progression of retinal degeneration | Statistical analysis using the data from Outcome 1, will be used to define variance between participants in rate of progression of retinal degeneration. | 5 years |
| Eye Institute of Alberta | Recruiting | Edmonton | Alberta | T5H 3V9 | Canada |
|
| Research Institute-McGill University Health Center | Recruiting | Montreal | Quebec | H4A 3J1 | Canada |
|
| Yergeau C, Coussa RG, Antaki F, Argyriou C, Koenekoop RK, Braverman NE. Zellweger Spectrum Disorder: Ophthalmic Findings from a New Natural History Study Cohort and Scoping Literature Review. Ophthalmology. 2023 Dec;130(12):1313-1326. doi: 10.1016/j.ophtha.2023.07.026. Epub 2023 Aug 2. |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D000015 | Abnormalities, Multiple |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D018901 | Peroxisomal Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D005128 | Eye Diseases |